Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 6/20 | 0.36 |
| ▸ | CA1 | P00915 | 4/20 | 0.36 |
| ▸ | CA9 | Q16790 | 2/20 | 0.36 |
| ▸ | CA5A | P35218 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MGLL | Q99685 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.33 |
| ▸ | GPR3 | P46089 | 1/20 | 0.32 |
| ▸ | MMP3 | P08254 | 1/20 | 0.32 |
| ▸ | MMP8 | P22894 | 1/20 | 0.32 |
| ▸ | MMP13 | P45452 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3684084 | 0.84 | ALDH1A1 (0.33) | CA2CA1MMP8MMP13ALDH1A1 | |
| SCHEMBL4249989 | 0.82 | DNMT1 (0.40) | CA2CA1CA9CA5AMAPT | |
| SCHEMBL4263921 | 0.80 | CA1 (0.40) | CA2CA1CA9MAPTSMN1; SMN2 | |
| SCHEMBL3683894 | 0.80 | PKM (0.41) | CA2CA1CA9PTGS1PTGS2 | |
| SCHEMBL4575025 | 0.78 | ALDH1A1 (0.37) | CA2CA1CA9MAPTHPGD | |
| SCHEMBL2786480 | 0.78 | PTGS2 (0.35) | CA2CA1PTGS1PTGS2CA12 | |
| SCHEMBL27304396 | 0.74 | SMN1; SMN2 (0.41) | CA2CA1CA9MAPTHPGD | |
| SCHEMBL2878845 | 0.74 | KEAP1 (0.37) | CA2CA1CA9CA5APTGS1 | |
| SCHEMBL29048521 | 0.73 | SMN1; SMN2 (0.55) | CA2CA1CA9MAPTHPGD | |
| SCHEMBL5023011 | 0.73 | CA12 (0.33) | CA2CA1MAPTHPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240369924-A1 | RESIST COMPOSITION AND RESIST FILM FORMING METHOD USING SAME | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2024-11-07 | — | — | US | disclosed |
| WO-2024168123-A1 | SYNTHESIS OF CORE 2 O-SIALYL LEWIS-X POLYSACCHARIDES | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2024-08-15 | — | — | WO | disclosed |
| US-10098974-B2 | Catalytic radiofluorination | THE GENERAL HOSPITAL CORPORATION (US) | 2018-10-16 | — | — | US | disclosed |
| US-20150132223-A1 | Catalytic Radiofluorination | THE GENERAL HOSPITAL CORPORATION | 2015-05-14 | — | — | US | disclosed |
| US-8900550-B2 | Catalytic radiofluorination | THE GENERAL HOSPITAL CORPORATION (US) | 2014-12-02 | — | — | US | disclosed |
| US-8524873-B2 | Sugar donor | RIKEN (JP) | 2013-09-03 | — | — | US | disclosed |
| US-20130115168-A1 | Catalytic Radiofluorination | THE GENERAL HOSPITAL CORPORATION (US) | 2013-05-09 | — | — | US | disclosed |
| US-8257680-B1 | Catalytic radiofluorination | THE GENERAL HOSPITAL CORPORATION (US) | 2012-09-04 | — | — | US | disclosed |
| US-20120207677-A1 | CATALYTIC RADIOFLUORINATION | THE GENERAL HOSPITAL CORPORATION | 2012-08-16 | — | — | US | disclosed |
| EP-1829884-B1 | Sugar donor | RIKEN (JP) | 2010-11-10 | — | — | EP | disclosed |
| WO-2008022319-A2 | CATALYTIC RADIOFLUORINATION | THE GENERAL HOSPITAL CORPORATION (US) | 2008-02-21 | — | — | WO | disclosed |
| US-20070208171-A1 | SUGAR DONOR | RIKEN (JP) | 2007-09-06 | — | — | US | disclosed |
| EP-1829884-A1 | Sugar donor | Riken (JP) | 2007-09-05 | — | — | EP | disclosed |
| US-6388059-B1 | CONTACTING GLYCOSIDE HAVING ANOMERIC SULFOSIDE WITH COMPOUND HAVING FREE HYDROXYL IN PRESENCE OF ORGANIC ACID ANHYDRIDE AND ALKENE TO SCAVENGE SULFENYL ESTERS; INCREASED YIELD WITH REDUCED BY-PRODUCT FORMATION | THE TRUSTEES OF PRINCETON UNIVERSITY | 2002-05-14 | — | — | US | disclosed |
| EP-1097163-A4 | IMPROVED GLYCOSYLATION METHOD USING SULFOXIDE DONORS | UNIV PRINCETON (US) | 2002-03-06 | — | — | EP | disclosed |
| EP-1097163-A1 | IMPROVED GLYCOSYLATION METHOD USING SULFOXIDE DONORS | Princeton University (US) | 2001-05-09 | — | — | EP | disclosed |
| WO-2000004035-A1 | IMPROVED GLYCOSYLATION METHOD USING SULFOXIDE DONORS | PRINCETON UNIVERSITY (US) | 2000-01-27 | — | — | WO | disclosed |
| US-5635612-A | Method of forming multiple glycosidic linkages in a single step | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 1997-06-03 | — | — | US | disclosed |
| EP-0377175-A2 | Pattern forming composition and process for forming pattern using the same | HITACHI, LTD. (JP) | 1990-07-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130115168-A1 | Catalytic Radiofluorination | ARSA, STS, KCNK18 | CA2 80/4885CA1 132/4885CA9 138/4885 |
| US-20070208171-A1 | SUGAR DONOR | GCK, G6PD, SLC2A4 | CA2 4287/4885CA1 4046/4885CA9 3255/4885 |
| US-10098974-B2 | Catalytic radiofluorination | ARSA, STS, KCNK18 | CA2 80/4885CA1 132/4885CA9 138/4885 |
| US-20150132223-A1 | Catalytic Radiofluorination | ARSA, KCNK18, STS | CA2 148/4885CA1 155/4885CA9 192/4885 |
| US-20120207677-A1 | CATALYTIC RADIOFLUORINATION | ARSA, STS, KCNK18 | CA2 80/4885CA1 132/4885CA9 138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.